A large amount of evidence from epidemiological, migration, intervention, genetic and animal studies suggest that salt intake plays an important role in regulating population blood pressure (BP). 1-6 At the same time, many trials of the effect on BP of reducing salt intake have been performed. Several meta-analyses of these trials 7-10 have consistently shown a significant reduction in BP in hypertensive individuals. However, there was controversy about the magnitude of the fall in BP in normotensives. In the two most recent meta-analyses, 8,10 it was claimed that the results showed that salt reduction had very little or no effect on BP in normotensive individuals.The authors concluded that a population reduction in salt intake is not warranted. However, these meta-analyses included trials with a very short duration of salt restriction, many for only five days, and also included trials of acute salt loading followed by severe and abrupt reductions in salt intake, i.e. from 20 grams of salt/day to less than 1 gram/day. It is known that an acute and large reduction in salt intake causes an increase in sympathetic tone 11 and also causes large compensatory increases in plasma renin activity (PRA) and angiotensin II (Ang II), which are particularly evident in normotensive individuals. 12 The results from these meta-analyses are, therefore, not useful in informing public health policy, which is for a more modest reduction in salt intake over a much more prolonged period of time. We recently carried out a meta-analysis that included only trials with modest reductions in salt intake, of the same order as the public health recommendations (i.e. a reduction in salt intake from approximately 10 g/day to approximately 5 g/day), and with a duration of four or more weeks. Our meta-analysis demonstrates that a modest reduction in salt intake does have a significant effect on systolic and diastolic BP in both hypertensive and normotensive individuals. Importantly, there was a dose response to salt restriction. 13 However, by far the most reliable estimate of the effect of reducing salt intake on BP now comes from the large and well-controlled DASH-Sodium trial (Dietary Approaches to Stop Hypertension), which was published early this year in the New England Journal of Medicine. 14 The trial was a multicentre, 14-week feeding study in which 412 subjects, 169 of whom were hypertensive and 243 normotensive, were randomised, in a parallel-group study to either consume a normal American diet or the DASH diet (i.e. rich in fruits, vegetables, and low-fat dairy products).They were then randomised into a crossover study of three salt intakes: approximately 8 g, 6 g and 4 g/day. The study provided participants with all of their food, assuring that subjects were eating their assigned diets.
A large amount of evidence from epidemiological, migration, intervention, genetic and animal studies suggest that salt intake plays an important role in regulating population blood pressure (BP). [1] [2] [3] [4] [5] [6] At the same time, many trials of the effect on BP of reducing salt intake have been performed. Several meta-analyses of these trials 7-10 have consistently shown a significant reduction in BP in hypertensive individuals. However, there was controversy about the magnitude of the fall in BP in normotensives. In the two most recent meta-analyses, 8, 10 it was claimed that the results showed that salt reduction had very little or no effect on BP in normotensive individuals.The authors concluded that a population reduction in salt intake is not warranted. However, these meta-analyses included trials with a very short duration of salt restriction, many for only five days, and also included trials of acute salt loading followed by severe and abrupt reductions in salt intake, i.e. from 20 grams of salt/day to less than 1 gram/day. It is known that an acute and large reduction in salt intake causes an increase in sympathetic tone 11 and also causes large compensatory increases in plasma renin activity (PRA) and angiotensin II (Ang II), which are particularly evident in normotensive individuals. 12 The results from these meta-analyses are, therefore, not useful in informing public health policy, which is for a more modest reduction in salt intake over a much more prolonged period of time. We recently carried out a meta-analysis that included only trials with modest reductions in salt intake, of the same order as the public health recommendations (i.e. a reduction in salt intake from approximately 10 g/day to approximately 5 g/day), and with a duration of four or more weeks. Our meta-analysis demonstrates that a modest reduction in salt intake does have a significant effect on systolic and diastolic BP in both hypertensive and normotensive individuals. Importantly, there was a dose response to salt restriction. 13 However, by far the most reliable estimate of the effect of reducing salt intake on BP now comes from the large and well-controlled DASH-Sodium trial (Dietary Approaches to Stop Hypertension), which was published early this year in the New England Journal of Medicine. 14 The trial was a multicentre, 14- week feeding study in which 412 subjects, 169 of whom were hypertensive and 243 normotensive, were randomised, in a parallel-group study to either consume a normal American diet or the DASH diet (i.e. rich in fruits, vegetables, and low-fat dairy products).They were then randomised into a crossover study of three salt intakes: approximately 8 g, 6 g and 4 g/day. The study provided participants with all of their food, assuring that subjects were eating their assigned diets.
The results showed that reducing salt intake lowered BP in hypertensive and normotensive individuals, both on the normal American diet and on the DASH diet. The lower the salt intake, the lower the BP (Figure 1 ). 14 On the normal American diet, when salt intake was reduced from 8-4 g/day, the average fall in BP was 8.7/4.5 mmHg in hypertensive and 5.3/2.6 mmHg in normotensive individuals. On the DASH diet, BP was lower, as found in the original DASH study, 15 but salt restriction still significantly lowered BP in both hypertensive and normotensive individuals.The combination of salt restriction and the DASH diet reduced BP by 11.5/5.7 mmHg and 7.1/3.7 mmHg in hypertensives and normotensives respectively.
The DASH-Sodium trial and most of the other clinical trials are relatively short in duration, i.e. a few weeks only. It is unlikely that salt restriction has achieved its maximum effect on BP within this time frame. Indeed, a longer-term, populationbased intervention study in two Portuguese villages 4 showed a greater effect on BP with a reduction in population salt intake than that observed in the short-term clinical trials. The reason that a few longer-term salt reduction trials [16] [17] [18] did not show a greater fall in BP compared with the shortterm trials, is likely to be due to poor compliance with the low-salt diet.
Although the mechanism whereby a reduction in salt intake lowers BP is not fully understood, several studies have shown that the fall in BP with salt restriction is significantly related to the responsiveness of the renin-angiotensin-aldosterone system (RAAS), i.e. the greater the rise in PRA and, thereby, Ang II with salt restriction, the smaller the fall in BP. [19] [20] [21] Salt restriction is, therefore, particularly effective in lowering BP in subjects who have a less responsive RAAS, such as blacks, the elderly, and hypertensives. The DASH-Sodium trial confirmed that salt restriction lowers BP to a greater extent in blacks compared with non-blacks, and in hypertensives compared with normotensives. 14 Our previous study with the use of an angiotensin-converting enzyme inhibitor (ACE-I), which blocks the formation of Ang II, has shown that moderate salt reduction caused a greater fall in BP in hypertensive patients who were already on captopril 22 compared with those who were not on any medication. 23 A further study has shown that moderate salt restriction is as effective as a thiazide diuretic when added to an ACE-I. 24 The new findings of the DASH-Sodium trial, combined with the findings of our meta-analysis, in conjunction with all of the previous evidence relating salt to BP, clearly makes a strong case for a reduction in population salt intake.The only controversy is how far to aim to reduce salt intake, in that it would appear, both from the DASH-Sodium trial and our meta-analysis, that the lower the salt intake, the better.A practical reduction is obviously called for and the current public health recommendations of reduction on average from approximately 10 to 5 gram/day seem to be appropriate.
A modest reduction in population salt intake would reduce population BP and therefore reduce cardiovascular mortality. Indeed, recently published follow-up data of 1173 Finnish men and 1263 women who had a 24-hour urinary sodium measured at baseline, has shown that a lower salt intake is significantly related to a lower cardiovascular mortality independent of other known car-diovascular risk factors. 25 Furthermore, there is increasing evidence that a modest reduction in salt intake has other beneficial effects on human health, for example a reduced risk of stomach cancer, a direct effect on stroke, left ventricular hypertrophy, progression of renal disease and proteinuria, independent of, and additional to, salt's effect on BP, a positive calcium balance with a reduced risk of renal stones and bone demineralisation. 26 In developed countries most salt in the diet comes from salt added to processed foods (for example, 80% in the UK).Therefore, any reduction in salt intake needs the cooperation of the food industry to make gradual and sustained reductions in the salt content of all processed foods. Some sectors of the food industry, such as the soft drinks, mineral water and processed meat industry, will strongly resist these changes for commercial reasons. Much of the heat generated in the so-called salt debate results from these vested interests. However, the DASH-Sodium trial now gives us clear evidence and we need to persuade the rest of the food industry to start reducing the salt concentration of processed foods. 
